PIRS News and Press, Pieris Pharmaceuticals Inc. From 05/22/19

BOSTON, MA / ACCESSWIRE / May 22, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced t...

CymaBay Therapeutics (NASDAQ: CBAY ) initiated with Buy rating and $21 (70% upside) price target at Citigroup. Shares up  1%  premarket. More news on: CymaBay Therapeutics, Inc., MannKind Corporation, Pieris Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , ...

BOSTON, MA / ACCESSWIRE / May 14, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that Allan Re...

Shares of Pieris Pharmaceuticals ( PIRS ) have fallen by 30% since my initial recommendation from August of 2017, where I highlighted management's partnering prowess as reflected in $4 billion in potential milestone payments the company stood to receive as multiple programs moved forward. Th...

Pieris Pharmaceuticals, Inc. (PIRS) Q1 2019 Results Earnings Conference Call May 10, 2019 08:00 AM ET Company Participants Allan Reine - Chief Financial Officer Stephen Yoder - CEO, President Louis Matis - Senior VP & Chief Development Officer Conference Call Participants ...

Pieris Pharmaceuticals ( PIRS ) Q1 results : Revenues: $8.5M (+102.4%). More news on: Pieris Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...

Pieris Pharmaceuticals (NASDAQ: PIRS ): Q1 GAAP EPS of -$0.20 misses by $0.02 . More news on: Pieris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Company To Host An Investor Conference Call On Friday, May 10, 2019 At 8:00 AM EDT BOSTON, MA / ACCESSWIRE / May 10, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® tec...

BOSTON, MA / ACCESSWIRE / May 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced th...

Founded by a Nobel prize winner, Bicycle Therapeutics ( BCYC ) has developed a large amount of intangible assets, which should interest investors. Besides, the company reports collaboration agreements with larger pharmaceutical institutions, cash in hand, and no debt. While Bicycle is still at...